Bristol Myers Squibb (CELG-RI) FCF Payout Ratio (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly FCF Payout Ratio of 0.42 for Q2 2026, up 17.44% year-over-year from 0.35 in Q2 2025, and down 75.41% quarter-over-quarter from 1.69 in Q1 2026.
Bristol Myers Squibb (CELG-RI) FCF Payout Ratio (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported FCF Payout Ratio for 18 consecutive years, with 0.42 the latest figure, recorded in Q2 2026.
- In Q2 2026, FCF Payout Ratio rose 17.44% year-over-year to 0.42; the TTM figure through Jun 2026 stood at 0.45 (up 31.06% YoY), while the FY2025 annual figure was 0.39, up 12.6% from the prior year.
- FCF Payout Ratio slipped to 0.42 in Q2 2026 per CELG-RI's latest filing, from 1.69 in the prior quarter.
- Across five years, FCF Payout Ratio topped out at 1.69 in Q1 2026 and bottomed at 0.01 in Q2 2022.
- Historically, FCF Payout Ratio has averaged 0.48 across 5 years, with a median of 0.37 in 2022.
- Annual changes were most pronounced in 2023 — FCF Payout Ratio surged 12086.9% — and 2025, when it tumbled 39.81%.
- Bristol Myers Squibb's FCF Payout Ratio stood at 0.39 in 2022, then retreated by 23.54% to 0.3 in 2023, then advanced by 1.41% to 0.3 in 2024, then surged by 162.33% to 0.79 in 2025, then plunged by 47.03% to 0.42 in 2026.
- Business Quant data shows CELG-RI's FCF Payout Ratio at 0.42 in Q2 2026, 1.69 in Q1 2026, and 0.79 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 0.44 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 0.99 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 0.48 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 0.52 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -3.54 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 0.39 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 0.30 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 8.12 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 0.42 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.42 |
| Mar 31, 2026 | 1.69 |
| Dec 31, 2025 | 0.79 |
| Sep 30, 2025 | 0.21 |
| Jun 30, 2025 | 0.35 |
| Mar 31, 2025 | 0.74 |
| Dec 31, 2024 | 0.30 |
| Sep 30, 2024 | 0.23 |
| Jun 30, 2024 | 0.59 |
| Mar 31, 2024 | 0.48 |
| Dec 31, 2023 | 0.30 |
| Sep 30, 2023 | 0.27 |
| Jun 30, 2023 | 0.74 |
| Mar 31, 2023 | 0.44 |
| Dec 31, 2022 | 0.39 |
| Sep 30, 2022 | 0.34 |
| Jun 30, 2022 | 0.01 |
| Mar 31, 2022 | 0.33 |
| Dec 31, 2021 | 0.29 |
| Sep 30, 2021 | 0.22 |